Research and clinical trials

Keratoconus can threaten vision; identifying risk factors helps clinicians and patients consider prevention, early detection, and targeted eye care. Some commonly encountered issues in people with IBD—like dry eye or...

This review organizes and grades causal evidence linking individual gut bacteria, their metabolites, and host pathways in IBD—helping researchers and clinicians see which microbe–metabolite mechanisms are best supported...

People with Crohn's disease or ulcerative colitis might see more AI-based prognostic tools in the literature, but this review shows most models are not yet proven ready for clinical use because they lack key validation...

This study maps how Crohn’s-associated genetic variants may act at a distance in specific immune cells (ILC3), revealing new candidate genes and mechanisms — including an unexpected role for CLN3 — that could point to...

Patients with ulcerative colitis who cannot tolerate 5-ASA need alternative maintenance options. This study suggests azathioprine showed comparable continuation, safety, and endoscopic outcomes whether or not patients...

If true, the study suggests that long-term air pollution exposure may raise the risk of developing IBD and that greater adherence to a plant-based diet could be linked with a lower pollution-related risk. That may be...

People with UC may be interested because the study identifies a traditional herbal formulation that reduced disease markers in a mouse model and changed gut microbiota and inflammatory pathways (IL‑17), suggesting...

Researchers are exploring non-drug enzyme-like catalysts to reduce oxidative stress in IBD—this study reports a new artificial antioxidase that helped reduce inflammation in cell and animal models, which could point to...

This project seeks to clarify how gut microbes and diet drive CD4+ T cell responses—mechanisms that are central to intestinal tolerance and to diseases like IBD. A better map of TCR–antigen pairs and how tolerance breaks...

Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...

Researchers are exploring a new way to block colon-homing T cells using a GPR15-targeting peptide; if successful, this could lead to a novel mechanism for treating IBD patients who don’t respond to current therapies.

Researchers are studying whether everyday microplastic exposure could worsen gut barrier injury in IBD and contribute to inflammatory or mental-health effects linked by the gut–brain axis.

Noninvasive stool metabolite patterns could eventually help predict which people with Crohn’s disease are more likely to develop strictures or penetrating complications, and may offer markers of disease activity and...

A Cochrane network meta-analysis compares many biologic medicines used for Crohn’s disease, which can help patients and clinicians understand how different drugs and drug classes stack up for inducing and keeping...

RDW is a cheap, routinely measured blood parameter; if it reliably reflects IBD presence or activity, it could be an easy additional tool to help detect flares or support assessment without extra testing.

Dysplasia is the key premalignant change that raises colorectal cancer risk in people with colonic IBD. Better detection and clearer management pathways can reduce cancer risk and help patients avoid unnecessary surgery.

This preclinical study links cod skin–derived collagen peptides to reduced colitis severity in mice through changes in the gut microbiota and suppression of the NLRP3 inflammasome — pathways that could be relevant to...

Researchers are exploring ways to produce anti-inflammatory proteins directly at inflamed gut sites; this study describes a nanomaterial system intended to protect plasmid drugs and supply oxygen to sustain local protein...

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Biomedical Signal Processing and Control.

This bibliometric analysis summaries recent Spanish research activity in IBD, showing where work is concentrated, the mix of clinical versus basic/translational studies, and gender representation in scientific...

This study explores a multi-component traditional medicine that the authors report can reduce experimental colitis and modulate inflammatory signaling and the gut microbiome — findings that could guide future preclinical...

The study identifies a new macrophage-driven immune pathway (VDAC1-mediated mtDNA release activating cGAS–STING) that contributes to ulcerative colitis in preclinical models and suggests a plant-derived compound (SEI)...

Improved automated classification of colonoscopy images could help detect polyps and signs of inflammatory bowel disease sooner, potentially supporting clinicians during endoscopy.

If you have IBD and take biologic therapy plus other medicines, inflammation and anti-cytokine treatment may change how your other drugs are metabolized. This review discusses ways researchers are trying to predict and...

People with Crohn’s disease who need a repeat ileocolic resection may wonder whether laparoscopic surgery is a good option. This study suggests laparoscopic attempts are often successful, and if conversion is needed...

This study reports an early-stage nanoplatform that combines targeted colon delivery of an aminosalicylate prodrug with scavenging of proinflammatory cfDNA, a dual strategy that reduced colitis severity in mice and could...

Predicting who will respond to anti-TNF drugs could help avoid ineffective treatments, reduce delays to effective therapy, and personalize care for children with Crohn's disease.

This study examines whether patterns of body size from birth through adulthood add information about IBD risk beyond adult BMI and genetic susceptibility. Results suggest life-course size trajectories may be more related...

This study suggests people with IBD have lower morning cortisol and a blunted cortisol awakening response, patterns that may be linked to systemic inflammation.

People with IBD face higher rates of anxiety, depression and other psychiatric disorders that often begin years before diagnosis and can persist long term. Recognizing and treating mental-health issues early can improve...

People with IBD are often interested in new, less toxic therapies that restore gut health. PEVs are an emerging microbiome-based approach that could one day offer targeted immune and barrier benefits without live...

This study describes a new clay-based nanotherapy that reduced inflammation and oxidative stress in a common mouse model of colitis, suggesting a potential local treatment approach that targets multiple disease...

The study describes a new oral delivery system designed to improve colon targeting and anti-inflammatory activity of celastrol, which could eventually lead to better drug options for ulcerative colitis if advanced to...

Bowel wall vascularization on ultrasound is used to gauge transmural inflammation in Crohn’s disease. This study examines whether quantitative measures could make those assessments more objective and how technique and...

Anti‑TNF drugs are a mainstay of IBD treatment. Understanding that they act through several immune mechanisms (not only neutralizing soluble TNF‑α) helps explain differences in effectiveness and informs conversations...

Virtual care reduced long-distance travel for IBD patients in remote Ontario, which both improves access to specialty care and appears to meaningfully lower travel-related CO2 emissions. Patients and clinics interested...

First‑degree relatives of people with IBD may worry about their own risk and consider diet as a way to reduce that risk. The study suggests how beliefs about genetics and diet influence whether relatives make preventive...

Patients and clinicians may care because the study suggests contrast-enhanced CT can reliably detect and localize IBD, including transmural and small-bowel disease that biopsies miss, which could affect diagnostic...

This pooled analysis focuses on children with IBD and reports that ustekinumab was associated with substantial clinical and steroid-free remission rates and a low incidence of serious adverse events—information that may...

The study presents a new edible nanoparticle that delivers resveratrol to the colon and improved disease markers in a mouse model of ulcerative colitis, which could inform future delivery strategies for plant-derived...

The review connects microbiome-targeted therapies (diet, probiotics, FMT, antibiotics, and newer approaches) to mechanisms relevant to IBD and systemic health, highlighting why these strategies are of interest to...

Handheld IUS could make noninvasive bowel assessment faster and more accessible for people with IBD, helping with triage and short-term monitoring without immediately resorting to endoscopy or advanced imaging.

If validated, metabolite patterns could help predict which children will reach remission on vedolizumab, potentially guiding treatment choices and avoiding ineffective therapy.

A blood antibody (anti-integrin αvβ6) was associated with relapse risk in UC and may help predict who stays in long-term remission, which could affect monitoring and treatment planning.

People with IBD face higher osteoporosis risk; this study looked for a genetic variant (LCT-13910C>T) that might affect bone density but found no clear link in this cohort, so it does not change current bone-health...

Patients with Crohn's who develop intra-abdominal abscesses often face decisions about antibiotics, drainage, or surgery. Predictors like abscess size and imaging appearance may help estimate the chance of needing...

The study points to a new inflammation mechanism (VDAC1 → mtDNA → cGAS–STING) that may drive ulcerative colitis and identifies a natural compound, SEI, that blocks it in lab and mouse models; this could guide future drug...

The paper identifies a new mechanism (VDAC1-driven mtDNA release activating cGAS–STING) that may drive inflammation in ulcerative colitis and a candidate compound (senkyunolide I) that blocks this pathway in preclinical...